Diagnostic criteria of autoimmune hepatitis
- PMID: 24418295
- DOI: 10.1016/j.autrev.2013.11.009
Diagnostic criteria of autoimmune hepatitis
Abstract
Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disorder characterised by female preponderance, elevated transaminase and immunoglobulin G levels, seropositivity for autoantibodies and interface hepatitis. Presentation is highly variable, therefore AIH should be considered during the diagnostic workup of any increase in liver enzyme levels. A set of inclusion and exclusion criteria for the diagnosis of AIH have been established by the International Autoimmune Hepatitis Group (IAIHG). There are two main types of AIH: type 1, positive for anti-nuclear (ANA) and/or anti-smooth muscle antibodies (SMAs) and type 2, defined by the presence of anti-liver kidney microsomal antibody type 1 (LKM-1) and/or anti-liver cytosol type 1 (LC-1) autoantibodies. The central role of autoantibodies in the diagnosis of AIH has led the IAIHG to produce a consensus statement detailing appropriate and effective methods for their detection. Autoantibodies should be tested by indirect immunofluorescence at an initial dilution of 1/40 in adults and 1/10 in children on a freshly prepared rodent substrate that includes kidney, liver and stomach sections to allow for the simultaneous detection of all reactivities relevant to AIH. Anti-LKM-1 is often confused with anti-mitochondrial antibody (AMA) if rodent kidney is used as the sole immunofluorescence substrate. The identification of the molecular targets of anti-LKM-1 and AMA has led to the establishment of immuno-assays based on the use of the recombinant or purified autoantigens. Perinuclear anti-nuclear neutrophil antibody (p-ANNA) is an additional marker of AIH-1; anti soluble liver antigen (SLA) antibodies are specific for autoimmune liver disease, can be present in AIH-1 and AIH-2 and are associated with a more severe clinical course. Anti-SLA are detectable by ELISA or radio-immuno-assays, but not by immunofluorescence. AIH is exquisitely responsive to immunosuppressive treatment, which should be instituted promptly to prevent rapid deterioration and promote remission and long-term survival.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
[Autoimmune hepatitis and overlap syndrome: diagnosis].Praxis (Bern 1994). 2002 Aug 21;91(34):1339-46. doi: 10.1024/0369-8394.91.34.1339. Praxis (Bern 1994). 2002. PMID: 12233264 Review. German.
-
[A retrospective study on the role of antibodies against soluble liver antigen (anti-SLA antibodies) and other autoantibodies in the diagnostics of autoimmune hepatitis].Ned Tijdschr Geneeskd. 2006 Mar 4;150(9):490-4. Ned Tijdschr Geneeskd. 2006. PMID: 16553048 Dutch.
-
Clinical significance of autoantibodies in autoimmune hepatitis.J Autoimmun. 2013 Oct;46:17-24. doi: 10.1016/j.jaut.2013.08.001. Epub 2013 Sep 7. J Autoimmun. 2013. PMID: 24016388 Review.
-
Autoantibodies and autoantigens in autoimmune hepatitis.Semin Liver Dis. 2002 Nov;22(4):339-52. doi: 10.1055/s-2002-35704. Semin Liver Dis. 2002. PMID: 12447706 Review.
-
Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview.Eur J Intern Med. 2002 Aug;13(5):293-303. doi: 10.1016/s0953-6205(02)00089-4. Eur J Intern Med. 2002. PMID: 12144908
Cited by
-
Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead.Immunol Res. 2025 Apr 7;73(1):67. doi: 10.1007/s12026-025-09622-9. Immunol Res. 2025. PMID: 40195209 Free PMC article. Review.
-
Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine.Biochem Med (Zagreb). 2021 Jun 15;31(2):020502. doi: 10.11613/BM.2021.020502. Epub 2021 Apr 15. Biochem Med (Zagreb). 2021. PMID: 33927550 Free PMC article. Review.
-
How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative.Immunol Res. 2021 Dec;69(6):594-608. doi: 10.1007/s12026-021-09233-0. Epub 2021 Oct 9. Immunol Res. 2021. PMID: 34625914
-
Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(-)CD69(+) subset proliferation.Drug Des Devel Ther. 2016 Jan 25;10:443-53. doi: 10.2147/DDDT.S92440. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26869766 Free PMC article.
-
Homogeneous Biosensing Based on Magnetic Particle Labels.Sensors (Basel). 2016 Jun 6;16(6):828. doi: 10.3390/s16060828. Sensors (Basel). 2016. PMID: 27275824 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources